Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company ...
It was quite a busy and eventful day for the company.
Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...
GlobalData on MSN19h
Bausch + Lomb wins FDA nod for enVista Envy range of intraocular lensesThe approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...
Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...
Mit aller Härte, die der Vater für nötig hält und die ihm selbst widerfahren ist, erzieht er den Sohn zum Hoferben. Doch der ...
TPG and Blackstone are teaming up to bid for Bausch + Lomb, with an expected valuation between $13 billion and $14 billion.
The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.
According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...
Die Aktien der Bausch + Lomb Corporation (BLCO) stiegen auf ein 52-Wochen-Hoch von 21,19 US-Dollar, was das gestiegene Vertrauen der Investoren widerspiegelt. Der Hersteller von Produkten für die Auge ...
enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for ...
One Bloomberg estimate projected the sale to value Bausch + Lomb at over $13 billion, making the deal potentially one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback